Vorapaxar, a Novel Antithrombotic Agent, Reduces Events but Increases Bleeding

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 - Cardiometabolic Health
Mary Mosley

Chicago, IL—When added to traditional antiplatelet therapy, vorapaxar, an investigational thrombin receptor antagonist, reduced the risk of myocardial infarction (MI), stroke, or cardiovascular (CV) death in patients with established ischemic heart disease or atherothrombotic vascular disease. The results of the secondary prevention Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P TIMI-50) trial were presented by lead investigator David A. Morrow, MD, MPH Associate Professor of Medicine at Harvard Medical School, and Director of the Samuel A. Levine Cardiac Unit in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, at the 2012 American College of Cardiology meeting.

Table 1
Bleeding Rates at 3 Years in the Total Population of the TRA 2°P TIMI-50 Trial.

The patients who took vor apaxar had significantly more bleeding events at 3 years (Table 1). Notably, vorapaxar was stopped after 2 years in patients with a history of stroke, because a higher risk of intracranial hemorrhaging (ICH) was found in patients with a history of stroke in the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. The primary end points of CV death, MI, stroke, hospitalization for ischemia, and urgent revascularization in TRACER were not significantly reduced, but its secondary end point was significantly reduced, and it became the primary end point of TRA 2°P, a maneuver the US Food and Drug Administration calls reactive revision to a protocol.

TRA 2°P TIMI-50, a randomized, double-blind, placebo-controlled, multinational study, followed 26,449 patients for a mean of 2.5 years. Enrollees had previous MI (67%), stroke (19%), or to peripheral arterial disease (PAD; 14%). The patients were randomized to vorapaxar (2.5 mg once daily) or to placebo in addition to standard antiplatelet therapy of aspirin and a thienopyridine in a large proportion of patients.

The primary end point of MI, stroke, or CV death occurred in 9.3% of the vor apaxar group and 10.5% of the placebo group—a significant 13% reduction. A 12% reduction was achieved with vor apaxar for the composite of CV death, MI, stroke, or urgent coro - nary revascularization (11.2% with vorapaxar vs 12.4% with placebo) and a 14% reduction for CV death or MI (7.3% with vor apaxar vs 8.2% with placebo).

The risk of bleeding with vorapaxar was greater in patients with a history of stroke or transischemic attack or those who weighed <60 kg. Patients with a prior MI had a significant 20% reduction in CV death, MI, or stroke. In patients with PAD, there was a small trend for a benefit, with a 6% reduction.

A Closer Look at Bleeding, by Subgroups

In the 5746 patients with a history of stroke, the absolute increase in the Thrombolysis In Myocardial Infarction non–coronary artery bypass graft major bleeding rate was 2%, ICH was 1.5%, and fatal bleeding was 0.2%. In the 20,699 patients without a history of stroke, bleeding rates were 0.7%, 0.2%, and 0.1%, respectively.

Table 2
GUSTO Moderate or Severe Bleeding at 3 Years in Subgroups.

The moderate or severe bleeding rates in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial at 3 years were higher with vorapaxar compared with placebo in patients >75 years, in those with lower weight, and in those with stroke or PAD at baseline (Table 2).

Vorapaxar is the first in a new class of investigational protease-activated receptor-1 antagonists. “This is the first study to show definitively that blocking pathways reduces the risk of suffering another cardiovascular event,” said Dr Morrow. The decrease in MI, stroke, or CV death was offset by the increase in moderate and severe bleeding, including ICH.

Careful patient selection will be necessary to balance the antithrombotic benefit of reduced events against this increased bleeding risk. The optimal patient cohort appears to be patients who were aged <75 years, those who weighed >60 kg, and those who have not had a prior stroke.

Related Items
Intensive Treatment Early in Type 1 Diabetes Produces Substantial Long-Term Benefits
Mary Mosley
August 2013, Vol 6 ADA 2013 Highlights published on October 8, 2013 in Lipids
Albiglutide, a GLP-1 Receptor Agonist, Effective in Various Treatment Scenarios in Patients with Type 2 Diabetes
Mary Mosley
August 2013, Vol 6 ADA 2013 Highlights published on October 8, 2013 in Emerging Therapies
Costs of Diabetes-Related Complications Reduced with Canagliflozin Monotherapy
Mary Mosley
August 2013, Vol 6 ADA 2013 Highlights published on October 8, 2013 in Health Economics
Resource Utilization and Costs: Comparing Saxagliptin and Sitagliptin
Mary Mosley
August 2013, Vol 6 ADA 2013 Highlights published on October 8, 2013 in Health Economics
Substantial Costs for Diabetes Are Consumed by the Diabetic Foot and Arthritis
Mary Mosley
August 2013, Vol 6 ADA 2013 Highlights published on October 8, 2013 in Health Economics
Last modified: July 16, 2012
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME